Global assays and the management of oral anticoagulation

被引：45
作者：
Brinkman H.J.M. [1 ]
机构：
[1] Sanquin Research, Department of Plasma Proteins, Plesmanlaan 125, Amsterdam
来源：
Thrombosis Journal | / 13卷 / 1期
关键词：
Anticoagulation reversal; Apixaban; APTT; Dabigatran; Prothrombin complex concentrate; PT; Rivaroxaban; Thrombin generation; Thromboelastography; Vitamin K antagonists;
D O I：
10.1186/s12959-015-0037-1
中图分类号：
学科分类号：
摘要：
Coagulation tests range from global or overall tests to assays specific to individual clotting factors and their inhibitors. Whether a particular test is influenced by an oral anticoagulant depends on the principle of the test and the type of oral anticoagulant. Knowledge on coagulation tests applicable in monitoring status and reversal of oral anticoagulation is a prerequisite when studying potential reversal agents or when managing anticoagulation in a clinical setting. Specialty tests based on the measurement of residual activated factor X (Xa) or thrombin activity, e.g., are highly effective for determining the concentration of the new generation direct factor Xa- and thrombin inhibitors, but these tests are unsuitable for the assessment of anticoagulation reversal by non-specific prohemostatic agents like prothrombin complex concentrate (PCC) and recombinant factor VIIa (FVIIa). Global coagulation assays, in this respect, seem more appropriate. This review evaluates the current status on the applicability of the global coagulation assays PT, APTT, thrombin generation and thromboelastography in the management of oral anticoagulation by vitamin K antagonists and the direct factor Xa and thrombin inhibitors. Although all global tests are influenced by both types of anticoagulants, not all tests are useful for monitoring anticoagulation and reversal thereof. Many (pre)analytical conditions are of influence on the assay readout, including the oral anticoagulant itself, the concentration of assay reagents and the presence of other elements like platelets and blood cells. Assay standardization, therefore, remains an issue of importance. © Brinkman.
引用
收藏
相关论文
共 112 条
[1]  
Mannucci P.M., Poller L., Venous thrombosis and anticoagulant therapy, Br J Haematol, 114, pp. 258-270, (2001)
[2]  
Wardrop D., Keeling D., The story of the discovery of heparin and warfarin, Br J Haematol, 141, pp. 757-763, (2008)
[3]  
Beck E.A., The chemistry of blood coagulation: a summary by Paul Morawitz (1905), Thromb Haemost, 37, pp. 376-379, (1977)
[4]  
Quick A.J., Stanley-Brown M., Bancroft F.W., A study of the coagulation defect in hemophilia and in jaundice, Am J Med Sci, 190, pp. 501-510, (1935)
[5]  
Owren P.A., Thrombotest, a new method for controlling anticoagulant therapy, Lancet, 274, pp. 754-758, (1959)
[6]  
Keeling D., Baglin T., Tait C., Watson H., Perry D., Baglin C., Et al., Guidelines on oral anticoagulation with warfarin - fourth edition, Br J Haematol, 154, pp. 311-324, (2011)
[7]  
Holbrook A., Schulman S., Witt D.M., Vandvik P.O., Fish J., Kovacs M.J., Et al., Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, 141, 2, (2012)
[8]  
Baron T.H., Kamath P.S., McBane R.D., Management of antithrombotic therapy in patients undergoing invasive procedures, N Engl J Med, 368, pp. 2113-2124, (2013)
[9]  
Jackson C.M., Esnouf M.P., Has the time arrived to replace the quick prothrombin time test for monitoring oral anticoagulant therapy?, Clin Chem, 51, pp. 483-485, (2005)
[10]  
Segal J.B., Dzik W.H., Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review, Transfusion, 45, pp. 1413-1425, (2005)
12345678910